Feb 17 2011
Genovis has acquired an exclusive license for a new technology that uses so-called upconverting nanoparticles as contrast agents in optical biomedical imaging.
Genovis is acquiring the license from Lumito, a LUAB company, including an option to acquire the technology as a whole.
The license grants exclusive rights to upconverting nanoparticles and to the technology required to detect particles in biological material. Genovis has already developed a technique for coating nanoparticles with a nontoxic surface that provides stability and good distribution in various organs and biological tissues. By combining Genovis’ technology with the acquired license Genovis will soon be able to offer a product on the technology front. The goal is to commercialize the technology within one year, primarily for the preclinical market, and ultimately to evaluate the clinical potential of this technology.
“For Genovis the license means that we can be on the leading edge of a new growing market with large potential. We will expand our customer base and complement our portfolio with yet another unique product. We’ve had the pleasure of learning about this exciting new technology at an early stage through Professor Stefan Andersson-Engels and his research group, who invented the concept. By combining their knowledge of optics with Genovis’ knowledge of nanoparticles within biomedicine we will be able to create a commercial product relatively quickly. We have already noticed interest in new optical nanoparticles, so we are truly looking forward to launching the product,” says Sarah Fredriksson, CEO of Genovis.
“By combining the technology that we developed at the Division of Atomic Physics at Lund University with Genovis’ extensive expertise in coating and functionalization of nanoparticles, we foresee the potential for exciting new opportunities to open up in optical biomedical imaging. Genovis appears be a highly suitable partner for commercializing this technology, so we are extremely pleased about this agreement,” says Stefan Andersson, professor of physics at Lund University.
“We believed in the commercial potential of this invention from Professor Stefan Andersson and his fellow researchers already at an early stage. For Lumito, the collaboration and license deal with Genovis mean a commercial product with large potential can be developed and fast-tracked to a growing market,” says Christine Widstrand, Senior Advisor, LUAB.
Source: http://www.genovis.com/